Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | NPY4R | P50391 | 6/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | NPY1R | P25929 | 4/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 3/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661328 | 0.88 | NPY4R (0.37) | NPY4RNPY1RNPY2RNPY5RCTSL | |
| SCHEMBL1661064 | 0.86 | NPY4R (0.48) | NPY4RACENPY1RNPY2RNPY5R | |
| SCHEMBL19252729 | 0.82 | CTSL (0.47) | FOLH1CTSL | |
| SCHEMBL1661928 | 0.81 | CTSL (0.47) | NPY4RNPY1RNPY2RNPY5RCTSL | |
| SCHEMBL1662044 | 0.78 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL1661320 | 0.77 | GRIA1 (0.43) | NPY4RNPY1RNPY2RNPY5RCTSL | |
| SCHEMBL17495217 | 0.74 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL1663148 | 0.73 | APC (0.51) | ACEFOLH1CTSL | |
| SCHEMBL12793611 | 0.73 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL11129760 | 0.72 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | PTGER4 4182/4885NPY4R 4859/4885MME 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.